샘플 요청 목록

 카트 문의
시장보고서
상품코드
1571947

세계의 기관지 확장제 시장

Bronchodilators
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 93 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

기관지 확장제 시장은 2030년까지 450억 달러에 달할 전망입니다.

2023년에 327억 달러로 추정된 기관지 확장제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 4.7%로 성장하여 2030년에는 450억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 천식 적응증은 복합 연간 성장률(CAGR) 5.4%로 성장을 지속하고, 분석 기간 종료 시 191억 달러에 달할 것으로 예측됩니다. 만성 폐색성 폐 질환 적응증 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 4.5%로 추정됩니다.

미국 시장은 88억 달러, 중국은 복합 연간 성장률(CAGR) 7.9%로 성장할 것으로 예측됩니다.

미국 기관지 확장제 시장은 2023년 88억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 예측 기간 동안 복합 연간 성장률(CAGR) 7.9%를 견인해 2030년까지 97억 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 2.4%와 3.9%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 3.1%로 성장할 것으로 예측됩니다.

세계 기관지 확장제 시장 - 주요 동향 및 촉진요인 요약

왜 기관지 확장제는 호흡기 질환 관리에 필수적인가?

기관지 확장제는 천식, 만성 폐색성 폐 질환(COPD), 기관지염 등 다양한 만성 및 급성 호흡기 질환의 관리에 사용되는 중요한 약물입니다. 주된 작용은 기관지의 근육을 이완시키고, 기도를 넓히고, 기도 저항을 감소시킴으로써 기류를 개선하고, 호흡 곤란, 천명, 흉부 압박감 등의 증상을 완화합니다. 기관지 확장제는 그 작용 기작에서 β2 작용제, 항콜린제, 메틸크산틴제의 3가지로 분류됩니다. 살부타몰과 호르모테롤과 같은 β2 작용제는 가장 널리 사용되며 폐의 β2 수용체를 자극하여 평활근을 이완시킴으로써 작용합니다. 이프라트로퓸이나 티오트로피움과 같은 항콜린제는 부교감 신경계를 억제하여 기관지 수축을 방지하고 기도 확장을 촉진합니다. 테오필린을 포함하는 메틸크산틴계 약물은 치료 지수가 좁기 때문에 현재는 별로 사용되지 않지만, 특정 복잡한 경우에는 여전히 역할을 합니다. 이러한 약물은 호흡기 질환의 중증도와 성질에 따라 흡입, 경구, 정맥내 등 다양한 경로로 투여될 수 있습니다. 흡입은 약물을 폐에 직접 투여하기 때문에 전신 부작용을 최소화하면서 신속한 완화를 가져올 수 있으며 여전히 바람직한 방법입니다. 기관지 확장제의 임상 효능은 특정 환자의 요구에 맞출 수 있음과 함께 호흡기 질환의 긴급 및 장기 관리 모두에서 필수적이며 환자의 QOL을 크게 향상시킵니다.

새로운 기관지 확장제 제제는 어떻게 치료 패러다임을 변화시키는가?

기관지 확장제 분야에서는 기존 치료법의 한계를 해결하고 환자의 예후를 개선하기 위해 새로운 제제와 전달 시스템이 개발되어 지난 10년간 큰 발전을 이루었습니다. 가장 주목할만한 동향 중 하나는 장기간의 증상 조절을 제공하고 빈번한 투여의 필요성을 줄이는 장기간 작용하는 기관지 확장제로의 전환입니다. 살메테롤과 같은 장시간 작용성 β2 작용제(LABA)와 티오트로피움과 같은 장시간 작용성 무스카린 길항제(LAMA)는 COPD와 중등증에서 중증 천식 유지 요법의 기초 치료가 되고 있습니다. 이 약들은 단독 또는 흡입 코르티코 스테로이드와 함께 사용하여 지속적인 기관지 확장 작용을 발휘하고 악화를 억제하며 전체 폐 기능을 향상시킵니다. 또 다른 중요한 발전은 여러 유형의 기관지 확장제와 항염증제를 하나의 장치에 통합 한 듀얼 및 트리플 조합 흡입기의 출현으로 치료 요법을 단순화하고 환자의 어드레싱 향상합니다. 예를 들어, LABA, LAMA, 흡입 코르티코스테로이드를 결합한 트리플 콤비네이션 흡입기는 기도 관리에 대한 종합적인 접근법을 제공하며 심각한 COPD 관리에서 인기를 끌고 있습니다. 게다가 디지털 센서가 장착된 스마트 흡입기와 같은 혁신적인 전달 기술은 약물 사용과 복용 어드히어런스의 실시간 모니터링을 가능하게 하여 환자 관리에 변화를 가져오고 있습니다. 이 장치는 환자와 헬스케어 제공업체 모두에게 피드백을 제공하고, 치료 계획을 최적화하고, 악화의 위험을 최소화하는 데 도움이 됩니다. 또한, 2기능성 무스카린-β작용제(MABA)와 같은 신규 작용기전을 가진 새로운 기관지 확장제가 임상시험에서 검토되고 있으며, 호흡기 질환에 대한 치료 수단의 추가 확대가 기대되고 있다.

기관지 확장제 시장을 형성하는 규제 및 임상 고려 사항은 무엇인가?

기관지 확장제 시장은 규제 정책, 임상 지침 및 안전 고려 사항이 복잡하게 얽혀 형성되어 있으며, 이들이 통합되어 이러한 치료법의 승인, 사용 및 상업적 성공을 결정합니다. 미국 식품의약국(FDA)과 유럽의약청(EMA)과 같은 규제기관은 승인을 받기 전에 기관지 확장제의 효능과 안전성을 입증하는 확고한 임상 증거를 요구합니다. 임상시험에서는 보통 강제호기량(FEV1)으로 측정되는 폐기능의 개선뿐만 아니라 증상빈도의 감소, 악화, 전체적인 QOL의 개선도 나타내야 합니다. 안전성은 주요 우려 사항이며, 특히 장기간 작용하는 약물의 경우 특정 환자 집단에서 잠재적인 심혈관 위험과 관련이 있습니다. 그 결과, 규제기관은 장기적인 안전성 결과를 모니터링하기 위해 시판 후 조사 및 리스크 관리 전략을 의무화합니다. 또한 Global Initiative for Chronic Obstructive Lung Disease(GOLD) 및 Global Initiative for Asthma(GINA)와 같은 조직의 임상 지침은 치료 알고리즘을 정의하고 질병의 중증도와 환자의 특성에 따라 특정 기관지 확장제 수업을 추천하는 데 중요한 역할을합니다. 이러한 지침은 정기적으로 새롭게 증거와 새로운 치료법을 반영하기 위해 업데이트되며 헬스케어 환경 전반의 처방 패턴에 영향을 미칩니다. 시장 진입은 또한 상환 정책과 비용 효과 분석의 영향을 받지만 이들은 국가마다 크게 다릅니다. 전통적인 기관지 확장제의 제네릭 의약품 소개는 시장 경쟁을 격화시키고 가격을 낮추고 접근을 확대하고 있지만 동시에 브랜드 제품에 어려움을 겪고 있습니다.

기관지 확장제 시장 성장의 주요 촉진요인은?

기관지 확장제 시장의 성장은 인구 역학 동향, 기술 혁신 및 헬스케어 요구의 진화를 반영하는 몇 가지 주요 요인에 의해 견인되고 있습니다. 주요 요인 중 하나는 호흡기 질환, 특히 COPD와 천식 세계의 유병률의 상승이며, 이들은 세계의 이환율과 사망률의 주요 원인 중 하나입니다. 인구 고령화, 도시화 진전, 담배 연기 및 산업 배출 가스와 같은 환경 오염물질에 대한 노출은 폐쇄성기도 질환의 효과적인 관리를 필요로 하는 환자 수 증가에 기여하고 있습니다. 또한 치료 효과를 높이고 치료 요법을 간소화함으로써 환자의 컴플라이언스를 향상시키고 입원을 줄이는 병용 요법으로의 시프트도 큰 추진력이 되고 있습니다. 지속적인 증상 통제를 제공하는 1일 1회 투여 옵션과 합제의 개척은 치료 어드히어런스가 과제인 신흥국 시장에서 특히 높게 평가되고 있습니다. 또한, 호흡기 및 스마트 흡입기와 같은 흡입기 설계의 기술적 진보는 특히 노인 및 소아 환자에게 사용하기 쉽고 효율적인 전달 시스템에 대한 수요에 부응하고 있습니다. 개인화 의학의 상승은 시장에 영향을 미치고 있으며 유전자, 표현형 및 바이오 마커프로파일을 기반으로 기관지 확장제 치료를 조정하는 것에 주목하고 있습니다. 또한 원격 의료 및 원격 모니터링 솔루션의 채택 확대로 실시간 질병 관리와 조기 개입을 지원하는 종합적인 호흡기 관리 모델에 기관지 확장제를 통합 할 수있는 새로운 기회가 탄생했습니다. 마지막으로, 신흥 시장에서의 헬스케어 지출 증가와 호흡기 관리 접근성 개선은 아시아태평양 및 라틴아메리카와 같은 지역에서 기관지 확장제 시장의 확대를 촉진하고 있습니다. 이러한 요인들이 결합되어 세계 기관지 확장제 시장의 성장을 뒷받침하고 호흡기 질환 관리에서 기관지 확장제의 지속적인 진화와 관련성을 보장합니다.

조사 대상 기업 예(총 42건)

  • Ache Laboratorios Farmaceuticos
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • BioMarck Pharmaceuticals
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Innoviva
  • MediciNova
  • Merck & Co., Inc.
  • Novartis Ag

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.10.24

Global Bronchodilators Market to Reach US$45.0 Billion by 2030

The global market for Bronchodilators estimated at US$32.7 Billion in the year 2023, is expected to reach US$45.0 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Asthma Indication, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$19.1 Billion by the end of the analysis period. Growth in the Chronic Obstructive Pulmonary Disease Indication segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.8 Billion While China is Forecast to Grow at 7.9% CAGR

The Bronchodilators market in the U.S. is estimated at US$8.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Bronchodilators Market - Key Trends and Drivers Summarized

Why Are Bronchodilators Essential in the Management of Respiratory Disorders?

Bronchodilators are vital medications used in the management of a range of chronic and acute respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. Their primary function is to relax the bronchial muscles, widen the airways, and reduce airway resistance, thereby improving airflow and alleviating symptoms like shortness of breath, wheezing, and chest tightness. Bronchodilators are classified into three main categories based on their mechanism of action: beta-2 agonists, anticholinergics, and methylxanthines. Beta-2 agonists, such as salbutamol and formoterol, are among the most widely used and work by stimulating the beta-2 receptors in the lungs, leading to smooth muscle relaxation. Anticholinergics, such as ipratropium and tiotropium, inhibit the parasympathetic nervous system, preventing bronchoconstriction and promoting airway dilation. Methylxanthines, including theophylline, are less commonly used today due to their narrow therapeutic index but still play a role in certain complex cases. These agents can be administered through various routes, including inhalation, oral, and intravenous forms, depending on the severity and nature of the respiratory condition. Inhalation remains the preferred method as it delivers the medication directly to the lungs, providing rapid relief with minimal systemic side effects. The clinical effectiveness of bronchodilators, combined with their ability to be tailored to specific patient needs, makes them indispensable in both emergency and long-term management of respiratory diseases, significantly enhancing patient quality of life.

How Are New Bronchodilator Formulations Transforming Treatment Paradigms?

The field of bronchodilators has witnessed significant advancements over the past decade, with new formulations and delivery systems being developed to address the limitations of traditional therapies and improve patient outcomes. One of the most notable trends is the shift towards long-acting bronchodilators, which provide prolonged symptom control and reduce the need for frequent dosing. Long-acting beta-2 agonists (LABAs) like salmeterol and long-acting muscarinic antagonists (LAMAs) such as tiotropium have become foundational treatments in the maintenance therapy of COPD and moderate to severe asthma. These agents, when used alone or in combination with inhaled corticosteroids, provide sustained bronchodilation, reduce exacerbations, and improve overall lung function. Another significant development is the advent of dual and triple combination inhalers that incorporate multiple classes of bronchodilators and anti-inflammatory agents in a single device, simplifying treatment regimens and enhancing patient adherence. For example, triple-combination inhalers that combine a LABA, a LAMA, and an inhaled corticosteroid are gaining traction in the management of severe COPD, offering a comprehensive approach to airway management. Additionally, innovative delivery technologies, such as smart inhalers equipped with digital sensors, are transforming patient care by enabling real-time monitoring of medication use and adherence. These devices can provide feedback to both patients and healthcare providers, helping to optimize treatment plans and minimize the risk of exacerbations. Moreover, emerging bronchodilators with novel mechanisms of action, such as bifunctional muscarinic-beta agonists (MABAs), are being explored in clinical trials, promising to further expand the therapeutic arsenal for respiratory conditions.

What Are the Regulatory and Clinical Considerations Shaping the Bronchodilator Market?

The bronchodilator market is shaped by a complex interplay of regulatory policies, clinical guidelines, and safety considerations, which together determine the approval, usage, and commercial success of these therapies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require robust clinical evidence demonstrating the efficacy and safety of bronchodilators before granting approval. Clinical trials must show not only improvements in lung function, typically measured by forced expiratory volume (FEV1), but also reductions in symptom frequency, exacerbations, and overall quality of life improvements. Safety is a major concern, particularly for long-acting agents, which have been associated with potential cardiovascular risks in certain patient populations. As a result, regulatory bodies often mandate post-marketing surveillance and risk management strategies to monitor long-term safety outcomes. Additionally, clinical guidelines from organizations like the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA) play a crucial role in defining treatment algorithms and recommending specific bronchodilator classes based on disease severity and patient characteristics. These guidelines are updated regularly to reflect new evidence and emerging therapies, influencing prescribing patterns across healthcare settings. Market access is further influenced by reimbursement policies and cost-effectiveness analyses, which vary significantly between countries. The introduction of generic versions of older bronchodilators has increased market competition, driving down prices and expanding access, but also creating challenges for branded products.

What Are the Key Drivers Behind the Growth of the Bronchodilator Market?

The growth in the bronchodilator market is driven by several key factors that reflect a confluence of demographic trends, technological innovations, and evolving healthcare needs. One of the primary drivers is the rising global prevalence of respiratory diseases, particularly COPD and asthma, which are among the leading causes of morbidity and mortality worldwide. Aging populations, increased urbanization, and exposure to environmental pollutants such as tobacco smoke and industrial emissions have contributed to a growing patient pool requiring effective management of obstructive airway diseases. Another significant driver is the shift towards combination therapies that offer enhanced therapeutic outcomes and simplify treatment regimens, thereby improving patient compliance and reducing hospitalizations. The development of once-daily dosing options and fixed-dose combinations, which provide sustained symptom control, has been particularly well-received in markets where treatment adherence is a challenge. Moreover, technological advancements in inhaler design, such as breath-actuated devices and smart inhalers, are meeting the demand for user-friendly and efficient delivery systems, especially for elderly and pediatric patients. The rise of personalized medicine is also influencing the market, with a growing focus on tailoring bronchodilator therapies based on genetic, phenotypic, and biomarker profiles, leading to more precise and individualized treatments. Additionally, the expanding adoption of telemedicine and remote monitoring solutions is creating new opportunities for integrating bronchodilators into comprehensive respiratory care models that support real-time disease management and early intervention. Finally, increased healthcare spending in emerging markets, coupled with improved access to respiratory care, is driving the expansion of the bronchodilator market in regions like Asia-Pacific and Latin America. Together, these factors are propelling the growth of the global bronchodilator market, ensuring its continued evolution and relevance in the management of respiratory diseases.

Select Competitors (Total 42 Featured) -

  • Ache Laboratorios Farmaceuticos
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • BioMarck Pharmaceuticals
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Innoviva
  • MediciNova
  • Merck & Co., Inc.
  • Novartis Ag

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bronchodilators - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Respiratory Diseases Drives Growth in the Bronchodilators Market
    • Here's How Increasing Incidence of Asthma and COPD Strengthens Business Case for Bronchodilator Therapies
    • Growing Demand for Long-Acting Bronchodilators Expands Addressable Market Opportunity in Chronic Respiratory Disease Management
    • Shift Towards Combination Inhalers Spurs Growth for Dual and Triple Therapy Bronchodilator Products
    • Rising Adoption of Bronchodilators in Pediatric Care Propels Demand for Child-Friendly Dosage Forms and Delivery Devices
    • Here's the Story: How Advancements in Inhaler Devices Enhance Market Potential for Innovative Bronchodilator Delivery Systems
    • Rising Preference for Portable and Discreet Inhalation Devices Throws the Spotlight On Smart Inhalers and Wearable Nebulizers
    • Here's How Rising Environmental Pollution Accelerates Demand for Bronchodilators in Managing Pollution-Induced Airway Conditions
    • Growing Utilization of Bronchodilators in Acute and Emergency Care Boosts Market Growth for Short-Acting Bronchodilator Formulations
    • Increasing Awareness and Early Diagnosis of Respiratory Conditions Strengthens Market Position of Bronchodilators in Preventative Care
    • Rising Adoption of Bronchodilators in Smoking Cessation Programs Enhances Market Potential in Pulmonary Rehabilitation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bronchodilators Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Sympathomimetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • JAPAN
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • CHINA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • EUROPE
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bronchodilators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • FRANCE
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • GERMANY
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bronchodilators by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • INDIA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bronchodilators by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bronchodilators by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • AFRICA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제